Pharmafile Logo

bevacizumab

- PMLiVE

Roche’s Gazyva/Gazyvaro approved by FDA for primary membranous nephropathy

This rare, chronic autoimmune disease can cause kidney failure if left untreated

- PMLiVE

Teva and Samsung Bioepis to commercialise two FDA-approved biosimilars in the US

Teva will get US commercialisation rights for Eticovo upon close and infliximab in Q3 2027

- PMLiVE

Fresenius and WuXi Biologics announce agreement to expand biosimilars pipeline

The agreement gives Fresenius exclusive option rights for up to 37 potential first-to-market biosimilar candidates

- PMLiVE

Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer

The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care

- PMLiVE

Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS

If approved, this treatment would offer a new option for the nearly one million Americans living with MS

- PMLiVE

Roche and Dualitas Therapeutics announce research collaboration worth up to $1bn

The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases

- PMLiVE

Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments

MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain

- PMLiVE

Sandoz announces collaboration agreement with Shanghai Henlius Biotech

The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company

- PMLiVE

Boehringer Ingelheim’s Jascayd approved by MHRA for idiopathic pulmonary fibrosis

This is the first treatment breakthrough in pulmonary fibrosis in over a decade

- PMLiVE

Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment

This is the first and only at-home subcutaneous treatment option for this disease

- PMLiVE

Oxford BioTherapeutics announces clinical milestones from its collaboration with Boehringer Ingelheim

The collaboration began in 2013 and was later expanded in 2020 and 2023

- PMLiVE

Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer

Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links